GENEDRIVE PLC — Regulatory Filings 2016

Sep 21, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3854K

Genedrive PLC

21 September 2016

RNS  

For release:  21 September 2016

Genedrive plc ("Genedrive" or the "Company")

Notice of Preliminary Results

Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that it will release its preliminary results for the twelve months ending 30 June 2016 on 11 October, 2016. A meeting for analysts will be held at 11am BST at 1 Cornhill, London, EC3V 3ND .

In a trading update on 2 August 2016, the Company announced that for the full year ended 30 June 2016, revenue for the full year was £5.0m, at the top end of its previous guidance of £4.6m - £5.0m (2015: £4.5m). EBITDA losses are expected to be in line with market expectations of £3.9m (£3.5m). Net cash at 30 June 2016 was £1.1m (2015: £4.9m). In addition, following the year-end the Company completed a placing of new ordinary shares which raised £6.05m net of expenses.

- Ends -

For further details please contact:

Genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

John Rylands: Finance Director

Peel Hunt LLP

James Steel                                                                                                                        +44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

Notes to Editors

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need or point of care diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

Genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORAKKDNBBKBNCB